Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012)

BACKGROUND: In the era of targeted therapy, whether patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are exempted from anthracycline usage in the neoadjuvant setting is controversial. OBJECTIVES: Our objective was to retrospectively analyze the differences in path...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Heyan, Maimaitiaili, Amina, Liu, Zhenzhen, Ling, Rui, Zhao, Yi, Yang, Hongjian, Liu, Yunjiang, Liu, Ke, Zhang, Jianguo, Mao, Dahua, Yu, Zhigang, Liu, Yinhua, Fu, Peifen, Wang, Jiandong, Jiang, Hongchuan, Zhao, Zuowei, Tian, Xingsong, Cao, Zhongwei, Wu, Kejin, Song, Ailin, Jin, Feng, He, Jianjun, Fan, Zhimin, Zhang, Huimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986903/
https://www.ncbi.nlm.nih.gov/pubmed/36891484
http://dx.doi.org/10.1177/17588359231156146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986903/
https://www.ncbi.nlm.nih.gov/pubmed/36891484
http://dx.doi.org/10.1177/17588359231156146

Ejemplares similares